Trial reportEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2014
Effects of transdermal testosterone treatment on inflammatory markers in elderly males.
Trial report in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Reduction of calprotectin and phosphate during testosterone therapy in aging men: a randomized controlled trial.Journal of endocrinological investigation · 2017Trial
- Correlation between pan immune inflammation value and testosterone deficiency risk increase.Scientific reports · 2025Article
- Dietary polyunsaturated fatty acid and risk of gout: a cohort study integrating genetic predisposition and metabolomics.European journal of epidemiology · 2025Article
- Cancer disrupts sex hormone-inflammation relationships: Analysis of ALI in males from NHANES 2007-2018.PloS one · 2025Article
- A review of the role of testosterone in the care of the critically ill patient.The Southern African journal of critical care : the official journal of the Critical Care Society · 2024Review
- Aging versus youth: Endocrine aspects of vulnerability for COVID-19.Reviews in endocrine & metabolic disorders · 2022Review
- Examining Male Predominance of Severe COVID-19 Outcomes: A Systematic Review.Androgens: clinical research and therapeutics · 2022Review
- The Anti-Inflammatory Effects of Testosterone.Journal of the Endocrine Society · 2019Review
- The Effects of Testosterone Deficiency and Its Replacement on Inflammatory Markers in Rats: A Pilot Study.International journal of endocrinology and metabolism · 2017Article
- Elderly men over 65 years of age with late-onset hypogonadism benefit as much from testosterone treatment as do younger men.Korean journal of urology · 2015Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
Abstract
objectiveDuring the male aging process, testosterone (T) levels progressively fall and inflammatory biomarkers increase. Although a relationship between these 2 phenomena has been tested in previous clinical trials, there is inconclusive evidence about the potential anti-inflammatory action of T.
methodsA total of 108 healthy males >65 years with serum T concentration <475 ng/dL were recruited by direct mailings to alumni of the University of Pennsylvania and Temple University and randomized to 60-cm2 T or a placebo patch for 36 months. Ninety-six subjects completed the trial. Information and stored serum specimens from this trial were used to test the hypothesis of the inhibitory effect of T on inflammation. We evaluated 70 males (42 in the T group) who had banked specimens from multiple time points available for assays of T, C-reactive protein (CRP), tumor necrosis factor (TNF)-α, soluble TNF-α receptor-1 (TNFR1), interleukin-6 (IL-6), and soluble IL-6 receptors (sIL6r and sgp130).
resultsThe mean age ± SD at baseline was 71.8 ± 4.9 years. Testosterone replacement therapy for 36 months did not induce significant decreases in inflammatory markers. A trend toward a significant increase was observed in the placebo group for TNF-α (P = .03) and sgp130 (P = .01). Significant differences in estimated means of TNFR1 (but not other inflammatory markers), with lower levels in the T group, were observed at the 36-month time point. In T-treated subjects we found an almost significant treatment x time interaction term TNFR1 (P = .02) independent of total body fat content as assessed by dual energy X-ray absorptiometry (DXA). No serious adverse effect was observed.
conclusionsTransdermal T treatment of older males for 36 months is not associated with significant changes in inflammatory markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.